Atezolizumab plus bevacizumab and tremelimumab plus durvalumab: how should we choose these two immunotherapy regimens for advanced hepatocellular carcinoma?

Detalles Bibliográficos
Autores principales: Hatanaka, Takeshi, Naganuma, Atsushi, Yata, Yutaka, Kakizaki, Satoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745629/
https://www.ncbi.nlm.nih.gov/pubmed/36523927
http://dx.doi.org/10.21037/hbsn-22-510

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745629/
https://www.ncbi.nlm.nih.gov/pubmed/36523927
http://dx.doi.org/10.21037/hbsn-22-510

Ejemplares similares